Immunex Receives Unsolicited Proposal from American Home Products for Acquisition

Strategic Insights -

Immunex Corporation, a biopharmaceutical company, received an unexpected proposal from American Home Products Corporation to acquire all outstanding shares of Immunex's common stock not held by AHP at $14.50 per share in cash. This move comes after AHP's indirect ownership of 54.6 percent of Immunex's common stock. Immunex's Board of Directors is actively reviewing this proposal and is committed to protecting the interests of all shareholders.

Key Takeaways:

  • The proposed acquisition price of $14.50 per share represents a significant premium for Immunex shareholders.
  • The Board will consider whether the offer fairly reflects the value of the company, taking into account potentially material information concerning the company and its prospects not yet publicly disclosed.
  • Immunex has a governance agreement with AHP that requires approval of two-thirds of the Board (excluding AHP-designated directors) and a fairness opinion from an independent banking firm before any offer can be presented to shareholders.
  • The company is currently evaluating the AHP offer with the assistance of outside financial and legal advisors to respond in a timely and appropriate manner.
  • Immunex remains committed to delivering high-quality products and service to its customers and collaborators, regardless of the outcome of the Board's consideration of the AHP offer.

Statistics:

  • AHP owns 54.6 percent of Immunex's common stock indirectly.
  • The proposed acquisition price of $14.50 per share represents a premium of [calculated based on current market value].
  • The company completed its analysis of the results of a Phase II randomized, placebo-controlled, blinded clinical study with TNF receptor in rheumatoid arthritis patients on November 1, 1995.
  • The study involved 180 patients randomized to receive one of three different doses of the TNF receptor or placebo via twice weekly injection for a period of 85 days.
  • Positive, statistically significant results in favor of treatment with TNF receptor were achieved with respect to multiple clinical endpoints.

Sources:

  • Immunex Corporation (1995, November 2). Immunex Receives Unsolicited Proposal from American Home Products for Acquisition. PR Newswire.
  • Immunex Corporation (1995, November 1). Immunex Completes Analysis of Phase II Study with TNF Receptor in Rheumatoid Arthritis Patients. PR Newswire.
  • Cambridge Healthcare Institute on Cytokines and Inflammation (1995). Meeting Program.